ICL670
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Transfusional Iron Overload
Conditions
Transfusional Iron Overload
Trial Timeline
Jun 1, 2003 → —
NCT ID
NCT01044186About ICL670
ICL670 is a phase 2 stage product being developed by Novartis for Transfusional Iron Overload. The current trial status is completed. This product is registered under clinical trial identifier NCT01044186. Target conditions include Transfusional Iron Overload.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01610297 | Approved | Completed |
| NCT01090323 | Phase 2 | Completed |
| NCT01044186 | Phase 2 | Completed |
Competing Products
6 competing products in Transfusional Iron Overload
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Deferasirox | Novartis | Phase 2 | 52 |
| deferasirox | Novartis | Pre-clinical | 23 |
| Deferasirox | Novartis | Phase 2 | 52 |
| deferasirox: | Novartis | Approved | 85 |
| Deferasirox | Novartis | Phase 3 | 77 |
| Core Study: Deferasirox + Core Study: Deferoxamine + Extension: deferoxamine to deferasirox + Extension: deferasirox to deferoxamine + Deferasirox + Deferoxamine | Novartis | Phase 2 | 52 |